(Press-News.org) Contact information: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes
Gladstone scientists discover how immune cells die during HIV infection; identify potential drug to block AIDS
Gladstone plans to launch Phase 2 trial with existing anti-inflammatory
SAN FRANCISCO, CA—December 19, 2013—Research led by scientists at the Gladstone Institutes has identified the precise chain of molecular events in the human body that drives the death of most of the immune system's CD4 T cells as an HIV infection leads to AIDS. Further, they have identified an existing anti-inflammatory drug that in laboratory tests blocks the death of these cells—and now are planning a Phase 2 clinical trial to determine if this drug or a similar drug can prevent HIV-infected people from developing AIDS and related conditions.
Two separate journal articles, published simultaneously today in Nature and Science, detail the research from the laboratory of Warner C. Greene, MD, PhD, who directs virology and immunology research at Gladstone, an independent biomedical-research nonprofit. His lab's Science paper reveals how, during an HIV infection, a protein known as IFI16 senses fragments of HIV DNA in abortively infected immune cells. This triggers the activation of the human enzyme caspase-1 and leads to pyroptosis, a fiery and highly inflammatory form of cell death. As revealed in the Nature paper, this repetitive cycle of abortive infection, cell death, inflammation and recruitment of additional CD4 T cells to the infection "hot zone" ultimately destroys the immune system and causes AIDS. The Nature paper further describes laboratory tests in which an existing anti-inflammatory inhibits caspase-1, thereby preventing pyroptosis and breaking the cycle of cell death and inflammation.
"Gladstone has made two important discoveries, first by showing how the body's own immune response to HIV causes CD4 T cell death via a pathway triggering inflammation, and secondly by identifying the host DNA sensor that detects the viral DNA and triggers this death response," said Robert F. Siliciano, MD, PhD, a professor of medicine at Johns Hopkins University, and a Howard Hughes Medical Institute investigator. "This one-two punch of discoveries underscores the critical value of basic science—by uncovering the major cause of CD4 T cell depletion in AIDS, Dr. Greene's lab has been able to identify a potential new therapy for blocking the disease's progression and improving on current antiretroviral medications."
The research comes at a critical time, as so-called AIDS fatigue leads many to think that HIV/AIDS is solved. In fact, HIV infected an additional 2.3 million people last year, according to UNAIDS estimates, bringing the global total of HIV-positive people to 35.3 million. Antiretroviral medications (ARVs) can prevent HIV infections from causing AIDS, but they do not cure AIDS. Further, those taking ARVs risk both a latent version of the virus, which can rebound if ARVs are discontinued, and the premature onset of diseases that normally occur in aging populations. Plus, some 16 million people who carry the virus do not have access to ARVs, according to World Health Organization estimates.
Seeking solutions for all these challenges, the new Gladstone discovery builds on earlier research from Dr. Greene's lab, published in Cell in 2010. This study showed how HIV attempts, but fails, to productively infect most of the immune system's CD4 T cells. In an attempt to protect the body from the spreading virus, these immune cells then commit "cellular suicide," leading to the collapse of the immune system—and AIDS.
After that research, the Gladstone scientists began to look for ways to prevent this process by studying exactly how the suicidal response is initiated. Working in the laboratory with human spleen and tonsil tissue, as well as lymph-node tissue from HIV-infected patients, the researchers found that these so-called abortive infections leave fragments of HIV's DNA in the immune cells. As described in Nature, pyroptosis ensues as immune cells rupture and release inflammatory signals that attract still more cells to repeat the death cycle.
"Our studies have investigated and identified the root cause of AIDS—how CD4 T cells die," said Gladstone Staff Research Investigator Gilad Doitsh, PhD, who is the Nature paper's lead author, along with Nicole Galloway and Xin Geng, PhD. "Despite some 30 years of HIV research, this key HIV/AIDS process has remained pretty much a black box."
Once the scientists discovered this key process, as described in Nature, they began to investigate how the body senses the fragments of HIV's DNA in the first place, before alerting the enzyme caspase-1 to launch an immune response in the CD4 T cells. To identify the so-called DNA sensor, the scientists found a way to genetically manipulate CD4 T cells in spleen and tonsil tissue. In doing so, they discovered that reducing the activity of a protein known as IFI16 inhibited pyroptosis, explained Zhiyuan Yang, PhD, a Gladstone postdoctoral fellow who is one of the paper's two lead authors.
"This identified IFI16 as the DNA sensor, which then sends signals to caspase-1 and triggers pyroptosis," says Kathryn M. Monroe, PhD, the Science paper's other lead author, who completed the research while a postdoctoral fellow at Gladstone. "We can't block a process until we understand all of its steps—so this discovery is critical to devising ways to inhibit the body's own destructive response to HIV. We have high hopes for the upcoming clinical trial."
The Phase 2 trial—which will test an existing anti-inflammatory's ability to block inflammation and pyroptosis in HIV-infected people—promises to validate a variety of expected advantages to this therapy. For example, by targeting the human body, or host, instead of the virus, the drug is likely to avoid the rapid emergence of drug resistance that often plagues the use of ARVs. The anti-inflammatory may also provide a bridge therapy for the millions without access to ARVs, while also reducing persistent inflammation in HIV-infected people already on ARVs. Many suspect this inflammation drives the early onset of aging-related conditions such as dementia and cardiovascular disease. By reducing inflammation, the drug might also prevent expansion of a reservoir of latent virus that hides in the body where it thwarts a cure for HIV/AIDS.
"This has been an absolutely fascinating voyage of discovery," said Dr. Greene, who is also a professor of medicine, microbiology and immunology at the University of California, San Francisco, with which Gladstone is affiliated. "Every time we turned over an 'experimental rock' in the studies, a new surprise jumped out."
INFORMATION:
Nature article coauthors Zhiyuan Yang, PhD, Kathryn M. Monroe, PhD, Orlando Zepeda, Stefanie Sowinski, PhD, and Isa Muños Arias also participated in this research at Gladstone. The research was supported by the National Institutes of Health grants R21 AI102782, P30 AI027763 (UCSF-Gladstone Center for AIDS Research), 1DP1036502 (Avant-Garde Award for HIV/AIDS Research), U19 AI0961133 (Martin Delaney CARE Collaboratory), the A.P. Giannini Postdoctoral Research Fellowship and the UCSF/Robert John Sabo Trust Award.
Science article coauthors Jeffrey R. Johnson, PhD, Xin Geng, PhD, Gilad Doitsh, PhD, and Nevan J. Krogan, PhD, also participated in this research at Gladstone. The research was supported by the National Institutes of Health grants R21 AI102782, P50 GM082250, P01 AI090935, P50 GM081879, P30 AI027763 (UCSF-Gladstone Center for AIDS Research), 1DP1036502 (Avant-Garde Award for HIV/AIDS Research), U19 AI0961133 (Martin Delaney CARE Collaboratory); and the A.P. Giannini Postdoctoral Research Fellowship.
About the Gladstone Institutes
Gladstone is an independent and nonprofit biomedical-research organization dedicated to accelerating the pace of scientific discovery and innovation to prevent, treat and cure cardiovascular, viral, immune and neurological diseases. Gladstone is affiliated with the University of California, San Francisco.
Gladstone scientists discover how immune cells die during HIV infection; identify potential drug to block AIDS
Gladstone plans to launch Phase 2 trial with existing anti-inflammatory
2013-12-20
ELSE PRESS RELEASES FROM THIS DATE:
Greater dietary fiber intake associated with lower risk of heart disease
2013-12-20
Greater dietary fiber intake associated with lower risk of heart disease
As little as 1 extra portion of wholegrains plus more fruit and vegetables can decrease risk
In recent years, a decline in both cardiovascular disease (CVD) and coronary heart disease ...
Nearly 8 percent of hip implants not backed by safety evidence
2013-12-20
Nearly 8 percent of hip implants not backed by safety evidence
Current device regulation process 'seems to be entirely inadequate,' warn researchers
The researchers say the current regulation process "seems to be entirely inadequate" and they call for a ...
Government's voluntary approach to improving hospital food is not working, argues expert
2013-12-20
Government's voluntary approach to improving hospital food is not working, argues expert
3 out of 5 hospital meals found to contain more salt than a Big Mac
In an article published on bmj.com today, she says the government has wasted more than £54 million ...
Many people with diabetes still lose vision, despite availability of vision-sparing treatment
2013-12-20
Many people with diabetes still lose vision, despite availability of vision-sparing treatment
Researchers blame lack of education about advances in preventive care
Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, ...
Salty surprise -- ordinary table salt turns into 'forbidden' forms
2013-12-20
Salty surprise -- ordinary table salt turns into 'forbidden' forms
High-pressure X-ray experiments violate textbook rules of chemistry
This news release is available in German. High-pressure experiments with ordinary table salt have produced ...
The black-white infant mortality gap: Large, persistent and unpredictable
2013-12-20
The black-white infant mortality gap: Large, persistent and unpredictable
EAST LANSING, Mich. — The unobservable factors that underpin the infant mortality gap between blacks and whites have persisted for more than 20 years and now appear to play a larger role than ...
Biologists find clues to a parasite's inconsistency
2013-12-20
Biologists find clues to a parasite's inconsistency
CAMBRIDGE, MA -- Toxoplasma gondii, a parasite related to the one that causes malaria, infects about 30 percent of the world's population. Most of those people don't even know they are infected, but ...
Electron 'antenna' tunes in to physics beyond Higgs
2013-12-20
Electron 'antenna' tunes in to physics beyond Higgs
Though it was hailed as a triumph for the "Standard Model" of physics – the reigning model of fundamental forces and particles – physicists were quick to emphasize that last year's discovery of the Higgs boson still ...
Opposing phenomena possible key to high-efficiency electricity delivery
2013-12-20
Opposing phenomena possible key to high-efficiency electricity delivery
The coexistence of two opposing phenomena might be the secret to understanding the enduring mystery in physics of how materials heralded as the future of powering our homes and communities ...
Electron's shapeliness throws a curve at supersymmetry
2013-12-20
Electron's shapeliness throws a curve at supersymmetry
A small band of particle-seeking scientists at Yale and Harvard has established a new benchmark for the electron's almost perfect roundness, raising doubts about certain theories that predict what lies beyond physics' ...
LAST 30 PRESS RELEASES:
How a broken bone from arm wrestling led to a paradigm shift in mental health: Exercise as a first-line treatment for depression
Alarming levels of microplastics discovered in human brain tissue, linked to dementia
Global neurology leader makes The Neuro world's first open science institute
Alpha particle therapy emerges as a potent weapon against neuroendocrine tumours
Neuroscience beyond boundaries: Dr. Melissa Perreault bridges Indigenous knowledge and brain science
Giant clone of seaweed in the Baltic Sea
Motion capture: In world 1st, M. mobile’s motility apparatus clarified
One-third of older Canadians at nutritional risk, study finds
Enhancing climate action: satellite insights into fossil fuel CO2 emissions
Operating a virtual teaching and research section as an open source community: Practice and experience
Lack of medical oxygen affects millions
Business School celebrates triple crown
Can Rhizobium + low P increase the yield of common bean in Ethiopia?
Research Security Symposium on March 12
Special type of fat tissue could promote healthful longevity and help maintain exercise capacity in aging
Researchers develop high-water-soluble pyrene tetraone derivative to boost energy density of aqueous organic flow batteries
Who gets the lion’s share? HKU ecologists highlight disparities in global biodiversity conservation funding
HKU researchers unveil neuromorphic exposure control system to improve machine vision in extreme lighting environments
Researchers develop highly robust, reconfigurable, and mechanochromic cellulose photonic hydrogels
Researchers develop new in-cell ultraviolet photodissociation top-down mass spectrometry method
Researchers develop innovative tool for rapid pathogen detection
New insights into how cancer evades the immune system
3 Ways to reduce child sexual abuse rates
A third of children worldwide forecast to be obese or overweight by 2050
Contraction inhibitors after 30 weeks have no effect on baby's health
Nearly 1 in 5 US college athletes reports abusive supervision by their coaches
THE LANCET: More than half of adults and a third of children and adolescents predicted to have overweight or obesity by 2050
Ideal nitrogen fertilizer rates in Corn Belt have been climbing for decades, Iowa State study shows
Survey suggests people with disabilities may feel disrespected by health care providers
U-Michigan, UC Riverside launch alliance to promote hydrogen-fueled internal combustion engines
[Press-News.org] Gladstone scientists discover how immune cells die during HIV infection; identify potential drug to block AIDSGladstone plans to launch Phase 2 trial with existing anti-inflammatory